Cystic Fibrosis Foundation distributed the following clinical trial update in March. Click the trial title to get more details.
March 11, 2019
Study to evaluate inhaled molgramostim in adults 18 years and older with cystic fibrosis
Status: Enrolling
Description: This study will look at the effectiveness of the inhaled drug molgramostim, a drug intended to treat infections in the lung.
Age: 18 Years and Older
Mutation: No Mutation Requirement
Fev1% Predicted: 30% or greater
Number of Visits: 19
Length of Participation: 72 weeks
ClinicalTrials.gov link: https://clinicaltrials.gov/ct2/show/NCT03597347